| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HLA-DR beta |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| (what is this?) (verify) | |
Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers. Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.
References
- Bayes M, Rabasseda X, Prous JR (November 2003). "Gateways to clinical trials". Methods and Findings in Experimental and Clinical Pharmacology. 25 (9): 747–771. PMID 14685303.
- Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, et al. (October 2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study". Leukemia & Lymphoma. 47 (10): 2147–2154. doi:10.1080/10428190600757944. PMID 17071489. S2CID 24080973.
- Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, et al. (December 2009). "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia". Leukemia & Lymphoma. 50 (12): 1958–1963. doi:10.3109/10428190903186486. PMC 8166408. PMID 19860603. S2CID 22328921.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |